GSK 650394

TargetMol
Product Code: TAR-T2622
Supplier: TargetMol
CodeSizePrice
TAR-T2622-2mg2mg£111.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2622-5mg5mg£136.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2622-1mL1 mL * 10 mM (in DMSO)£144.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2622-10mg10mg£164.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2622-25mg25mg£254.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2622-50mg50mg£390.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2622-100mg100mg£527.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2622-200mg200mg£631.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2622-500mg500mg£1,131.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
GSK650394 is a serum- and glucocorticoid-regulated kinase-1 inhibitor.
CAS:
890842-28-1
Formula:
C25H22N2O2
Molecular Weight:
382.463
Pathway:
Microbiology/Virology; Metabolism
Purity:
0.9893
SMILES:
OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1
Target:
SGK; Influenza Virus

References

1. Sherk AB, et al. Cancer Res. 2008, 68(18), 7475-7483. 2. Anacker C, et al. Proc Natl Acad Sci U S A. 2013, 110(21), 8708-8713. 3. Alamares-Sapuay JG, et al. J Virol. 2013, 87(10), 6020-6066. 4. Peng HY, et al. Spinal SGK1/GRASP-1/Rab4 is involved in complete Freund's adjuvant-induced inflammatory pain via regulating dorsal horn GluR1-containing AMPA receptor trafficking in rats. Pain. 2012 Dec;153(12):2380-92. 5. Peng HY, et al. Spinal serum-inducible and glucocorticoid-inducible kinase 1 mediates neuropathic pain via kalirin and downstream PSD-95-dependent NR2B phosphorylation in rats. J Neurosci. 2013 Mar 20;33(12):5227-40.